SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns quarterly results and outlook topped expectations, but the muted, sometimes negative share reaction sparked a sell-the-news debate over whether strong AI-driven memory demand is already priced in. Bulls cite tight supply and durable demand, while skeptics point to high expectations, rising capital spending and memorys cyclical history.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Microns earnings beat and optimistic outlook for AI-driven memory demand are the main focus, with traders looking to the results as a read-through for Sandisks NAND business. Bulls expect a sympathy move on tight memory supply, while others are frustrated by SNDKs muted price reaction and warn that high expectations, valuation concerns, and broader risk-off conditions could weigh on the stock.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Wells Fargos view that the recent rise in AppLovin Pixel installs was concentrated in low-traffic storefronts, rather than signaling meaningful e-commerce growth, has fueled concern about the expansion and pressure on the shares. Traders are split: some see a growth warning, while others dispute the analysts interpretation and call the selloff an overreaction.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Traders are reacting to reports that Evernorths business-combination vote passed, advancing its planned Nasdaq listing as an XRP treasury company. The conversation is broadly bullish on XRPN and its warrants, but traders are still watching for official redemption details and closing timing, with some warning about SPAC volatility, dilution, and possible halts.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets AI push is driving attention, particularly claims of strong Gemini 4 benchmarks and Project Suncatchers planned test of TPU chips in orbit. Bullish traders view these as signs of product and infrastructure momentum, while others remain frustrated by choppy trading and Googles perceived lag versus peers.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

A SemiAnalysis report that OpenAIs latest Ultrafast model tier reportedly runs on Nvidia GPUs rather than Cerebras hardware has raised concerns about Cerebras major customer relationship; the claim is unconfirmed, and traders debate whether it affects the companys existing commitment. Expected insider share unlocks and selling are adding to the bearish pressure, while some investors view the decline as a buying opportunity.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Positive 24-month HOPE-3 extension data for Capricors Duchenne muscular dystrophy therapy deramiocelshowing slower upper-limb declinehas renewed attention ahead of the FDA decision. Traders see the results as supportive, while others argue they may not resolve the FDAs earlier statistical concerns; short-squeeze talk remains speculative.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid choppy tech trading and elevated Treasury yields, with traders debating whether bond-market pressure will weigh on AI-heavy Nasdaq stocks or be shrugged off as dips are bought. Microns results are also seen as a test for the AI and semiconductor trade, while bullish momentum calls compete with warnings of a broader pullback.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

A Delaware judge ruled that Liquidias Yutrepia infringes two valid United Therapeutics patent claims related to PH-ILD, prompting a sharp selloff as traders weigh possible limits on the drugs availability. Liquidia plans to pursue an appeal and remove the PH-ILD indication from the label; the community is split between viewing the ruling as a serious threat and calling the decline an overreaction.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is drawing attention over reports of potential talks to acquire UK digital bank Monzo, followed by the companys clarification that it is not pursuing a transaction. Traders are split between viewing a deal as a costly, potentially dilutive expansion and welcoming the clarification, with the shifting reports prompting sharp volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NVAX $BCTX $MRNA on my quest for the Holy Grail , everything coming together.  An off shelf personalized cancer treatment that would be highly effective and also available cheaply worldwide wide that insurers would gladly pay for. 
Matrix m the power house adjuvant that will turn cold tumors hot. 2nd generation mRNA that will turn cold tumors hot like iOncologi and glioblastoma. Moderna neoantigen personalized vaccine with Merck going to fail miserably to a small micro micro micro cap BCTX which I ran across researching matrix m compatible oncolgy companies. Many bringing up multiple other companies that might be Moderna’s competitor. The direct competitor that targets the same patient population at a fraction of the cost is Bctx.
That one just triggered my famous PRE Super Golden Cross technical signal. 
Moderna? An overpriced overhyped mRNA platform. Novavax? Anybody say 100 please.

AliceFireSteam

Stefan Stefanov

Douggie F

Jim Mason

SirWins

Jon Derrick

StockTwits for iOS

Novavax Inc

BriaCell Therapeutics Corp

Moderna Inc

 on my quest for the Holy Grail , everything coming together.  An off shelf personalized cancer treatment that would be highly effective and also available cheaply worldwide wide that insurers would gladly pay for. 
Matrix m the power house adjuvant that will turn cold tumors hot. 2nd generation mRNA that will turn cold tumors hot like iOncologi and glioblastoma. Moderna neoantigen personalized vaccine with Merck going to fail miserably to a small micro micro micro cap BCTX which I ran across researching matrix m compatible oncolgy companies. Many bringing up multiple other companies that might be Moderna’s competitor. The direct competitor that targets the same patient population at a fraction of the cost is Bctx.
That one just triggered my famous PRE Super Golden Cross technical signal. 
Moderna? An overpriced overhyped mRNA platform. Novavax? Anybody say 100 please.